Patient Preference for Subcutaneous Versus Intravenous Administration With Every 6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Patient Preference for Subcutaneous Versus Intravenous Administration With Every 6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

 The above infographic represents the opinions of the authors.  For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). 

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Adis Journals on behalf of, Wiendl, Heinz, Foley, John, Defer, Gilles, Ryerson, Lana Zhovtis, Cohen, Jeffrey A., L. Arnold, Douglas, Butzkueven, Helmut, Cutter, Gary R, Giovannoni, Gavin, Killestein, Joep, Domingo-Horne, Rose, Toukam, Marie, Nunn, Aimie, Maghzi, Amir-Hadi, Kuhelj, Robert, Lasky, Tyler
Format: Video
Sprache:eng
Schlagworte:
FOS: Clinical medicine
Medicine
Neurology and Neuromuscular Diseases
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung: The above infographic represents the opinions of the authors.  For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). 
DOI:10.6084/m9.figshare.26159224